PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023

1 year ago

Company aims to commercialize wholly-owned KETARX™ (racemic ketamine) for mental health, neurological and pain disorders Company aims to seek FDA…

Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing

1 year ago

COLUMBUS, Ohio, Jan. 11, 2023 (GLOBE NEWSWIRE) --  Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term…

Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23

1 year ago

SALT LAKE CITY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its…

BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™

1 year ago

BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…

Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

1 year ago

Research collaboration to target severe form of genetic dilated cardiomyopathyCollaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac…

Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference

1 year ago

Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing…

CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference

1 year ago

ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on…

Recce Pharmaceuticals to be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives

1 year ago

SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic…

Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors

1 year ago

DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic…